Recursion Pharmaceuticals reports fourth-quarter and full-year 2025 results Wednesday before the market opens, with investors scrutinizing whether the AI-driven biotech can translate its massive data ...

Java Development Kit (JDK) 26, a planned update to standard Java due March 17, 2026, has reached its second release candidate (RC) stage. The RC is open for critical bug fixes, with the feature set ...

Artificial intelligence is entering the era of self-improvement. On Thursday afternoon, OpenAI released a new cutting-edge coding model that the company said assisted in its own creation.

Abstract: Computing in memory (CIM) realizes energy-efficient neural network algorithms by implementing highly parallel multiply-and-accumulate (MAC) operation. However, the MAC delay of CIM will ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Billerica battery startup ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...

The de-risking event relates to the acquisition of the 50% interest in an ENPP1 inhibitor program (REV102) that it didn't own from Rallybio (NASDAQ: RLYB). REV102 is being developed to treat ...

Yes, Java certification is still worth it, but it pays to know which ones will help you stand out. Here's what you need to know about Java course certificates and hiring in 2025. Java, which turns 30 ...

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...